ALASCCA trial

ALASCCA is a prospective, randomized, double blinded, placebo controlled, multicenter, biomarker-based study of adjuvant treatment with ASA in colorectal cancer. A total of 3,900 patients will be screened. The primary objective of ALASCCA is to determine whether adjuvant treatment with 160 mg ASA once daily for 3 years can improve time to recurrence in patients with colorectal cancer with somatic alterations in the PI3K signaling pathway.


Study Documents
ALASCCA Protocol V4
ALASCCA Protocol V4 Synopsis
Översikt ALASCCA-studien


Contact

Principal Investigator (PI)
Anna Martling
Phone: 08-517 728 02
Organizational unit: Colorectal Surgery
E-mail: Anna.Martling@ki.se

Project leader ALASCCA
Sabine Süllow Barin
Organizational unit: Colorectal Surgery
E-mail: Sabine.Sullow.Barin@ki.se
Cell phone: +46-73-712 1354


Flowchart



Page last updated on 23-06-2016

ki.se